Business
INVO Bioscience to Report Fourth Quarter and Fiscal Year 2021 Financial Results on Thursday, March 31, 2022
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., March 24, 2022 /PRNewswire/ -- INVO
About this update from Invo Fertility, Inc.
[{"type":"text","content":"Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET\nSARASOTA, Fla., March 24, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its fourth quarter and fiscal year 2021, ended December 31, 2021, after the market close on Thursday, March 31, 2022. The Company has scheduled a conference call that same day, Thursday, March 31, 2022, at 4:30 pm ET, to review the results.\n\n \n \n \n \n \n \n\n \nFourth Quarter 2021 Conference Call Details\nDate and Time: Thursday, March 31, 2022, at 4:30 pm ET\nCall-in Information: Interested parties can access the conference call by dialing 833-756-0861 or 412-317-5751.\nLive Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/ or https://app.webinar.net/ELRqV6y23Y9. \nReplay: A teleconference replay of the call will be available through April 7, 2022, at 877-344-7529 or 412-317-0088, replay access code # 1918743. A webcast replay will be available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/ for 90 days. \nAbout INVO Bioscience\nWe are a medical device company focused on creating simplified, lower-cost treatments for patients diagnosed with infertility. Our solution, the INVO® Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell® is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase the availability of care. For more information, please visit htt...